R3i Previous events
1 September 2019
Addressing residual vascular risk :
Is a new therapy on the horizon?
Detailed report >
R31 & IAS Press Conference
Paris, France
24 November 2018
The Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARMa) Concept
Detailed report >
New Joint Initiative of the International Atherosclerosis Society (IAS) and Residual Risk Reduction Initiative (R3i) on the concept of SPPARM-a
Chantilly, France
10 June 2017
MSDA 2017 - 12th Metabolic Syndrome, type II Diabetes and Atherosclerosis Congress
Detailed report >
MSDA 2017 - 12th Metabolic Syndrome, type II Diabetes and Atherosclerosis Congress
Saint Petersburg, Russia
28 November 2014
VAS and R3i Multidisciplinary Joint Scientific Session “Residual Risk”
Detailed report >
VAS 11th European Angiology Days
Uggiate Trevano (Como), Italy
18 September 2014
Preventive cardiology R3i session
Detailed report >
PEDIM 2014 - Prague European Days of Internal Medicine
Prague, Czech Republic
12 September 2014
MSDA Kyoto 2014 - A highlight of R3i activities
Detailed report >
9th Metabolic syndrome, Type 2 Diabetes and Atherosclerosis Congress (MSDA 2014)
Kyoto, Japan
29 July 2014
CASMU R3i Symposium : Una actualización en dislipemias aterogénicas
Detailed report >
La formación médica continua de la Escuela de Graduados, por encargo del Departamento de Cardiología de CASMU
Montevideo, Uruguay
22 March 2014
R3i Goes Global: Latin America launch at SOCESP
Detailed report >
Sociedade de Cardiologia do Estado de Sao Paulo Congress (SOCESP 2014)
Sao Paulo, Brazil
4 October 2013
R3i symposium : Residual Risk – What does it mean? How to influence it?
Detailed report >
12th European Congress of Internal Medicine
Prague, Czech Republic
